BEGIN:VCALENDAR VERSION:2.0 PRODID:-//app.ishl.eu//Schedule X-WR-CALNAME:ISHL9 CALSCALE:GREGORIAN BEGIN:VTIMEZONE TZID:Europe/Berlin TZURL:http://tzurl.org/zoneinfo-outlook/Europe/Berlin X-LIC-LOCATION:Europe/Berlin BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:19700329T020000 RRULE:FREQ=YEARLY;BYMONTH=3;BYDAY=-1SU END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:19701025T030000 RRULE:FREQ=YEARLY;BYMONTH=10;BYDAY=-1SU END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTAMP:20260414T234200 UID:session-41@app.ishl.eu/2013 DTSTART;TZID=Europe/Berlin:20131012T083000 DTEND;TZID=Europe/Berlin:20131012T134500 SUMMARY:Hematology Educational - Hematology Educational LOCATION:Pipin II (Dorint Hotel) DESCRIPTION:Talks: Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL), Aggressive Non-Hodgkin-Lymphoma (NHL), Multiple Myeloma (MM), Chronic Myeloid Leukemia (CML) X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Hematology Educational - Hematology Educational ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260414T234200 UID:session-42@app.ishl.eu/2013 DTSTART;TZID=Europe/Berlin:20131012T100000 DTEND;TZID=Europe/Berlin:20131012T113000 SUMMARY:Workshop 1 - Prognostic and biomarkers – tissue and serum / plasma LOCATION:Pipin II (Dorint Hotel) DESCRIPTION:Talks: The immunomodulatory and angiogenic protein Galectin 1 is a circulating biomarker in Hodgkin Lymphoma, Plasma TARC as a treatment response marker and prognostic tissue biomarkers in classical Hodgkin Lymphoma, Prognostic biomarkers from gene expression pro ling in formalin- xed para n-embedded biopsies, Flow cytometry studies of lymphocyte predominant cells from nodular Lymphocyte Predominant Hodgkin Lymphoma, Identication of CD8 ‘follicularcytotoxic’ cells in tumor infiltrating T cells from classical Hodgkin Lymphoma X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Workshop 1 - Prognostic and biomarkers – tissue and serum / plasma ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260414T234200 UID:session-43@app.ishl.eu/2013 DTSTART;TZID=Europe/Berlin:20131012T100000 DTEND;TZID=Europe/Berlin:20131012T113000 SUMMARY:Workshop 2 - Closed workshop for pediatric groups LOCATION:Sandkaul (Dorint Hotel) DESCRIPTION:Talks: Overview of international harmonization of staging and response criteria in pediatric Hodgkin Lymphoma – summary of results thus far, Highlights and controversies found between existing major pediatric groups, Discussion X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Workshop 2 - Closed workshop for pediatric groups ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260414T234200 UID:session-44@app.ishl.eu/2013 DTSTART;TZID=Europe/Berlin:20131012T120000 DTEND;TZID=Europe/Berlin:20131012T133000 SUMMARY:Workshop 3 - GHSG Workshop LOCATION:Martin & Augustin (Dorint Hotel) DESCRIPTION: X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Workshop 3 - GHSG Workshop ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260414T234200 UID:session-45@app.ishl.eu/2013 DTSTART;TZID=Europe/Berlin:20131012T120000 DTEND;TZID=Europe/Berlin:20131012T133000 SUMMARY:Workshop 4 - Radiotherapy of Hodgkin Lymphoma in 2013 LOCATION:Pipin II (Dorint Hotel) DESCRIPTION:Talks: New concepts of eld and dose: Implications for disease control and long-term outcome, The role of radiotherapy in early stage and the relevance of PET response, Is radiotherapy still relevant for patients with advanced stage disease and in salvage of chemotherapy failures? X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Workshop 4 - Radiotherapy of Hodgkin Lymphoma in 2013 ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260414T234200 UID:session-46@app.ishl.eu/2013 DTSTART;TZID=Europe/Berlin:20131012T120000 DTEND;TZID=Europe/Berlin:20131012T133000 SUMMARY:Workshop 5 - Challenges in the development of new drugs in HL LOCATION:Severin (Dorint Hotel) DESCRIPTION:Talks: Progress on new drug development in Hodgkin Lymphoma, Clinical trials design, response assessment, and trial end points, Challenges of translation of abundant new data into clinical trials in rare diseases, Challenges of preclinical models X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Workshop 5 - Challenges in the development of new drugs in HL ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260414T234200 UID:session-48@app.ishl.eu/2013 DTSTART;TZID=Europe/Berlin:20131012T140000 DTEND;TZID=Europe/Berlin:20131012T153000 SUMMARY:Workshop 6 - New technologies for improving the therapeutic ratio of RT in HL LOCATION:Pipin II (Dorint Hotel) DESCRIPTION:Talks: Optimizing and using imaging for RT planning, Advanced conformal RT for reduction of normal organ exposure, Techniques for reduction of breast exposure, Breath-hold techniques, Proton therapy for Hodgkin Lymphoma, Early detection of breast cancer X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Workshop 6 - New technologies for improving the therapeutic ratio of RT in HL ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260414T234200 UID:session-49@app.ishl.eu/2013 DTSTART;TZID=Europe/Berlin:20131012T140000 DTEND;TZID=Europe/Berlin:20131012T153000 SUMMARY:Workshop 7 - PET LOCATION:Pipin I (Dorint Hotel) DESCRIPTION:Talks: The new NCCN guidelines and the role of PET / CT, Imaging and PET / CT recommendations for the revised staging and response criteria, Metabolic tumor volume and other new concepts, qPET – a quantitative approach to assess response in interim FDG-PET scans in lymphoma X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Workshop 7 - PET ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260414T234200 UID:session-50@app.ishl.eu/2013 DTSTART;TZID=Europe/Berlin:20131012T140000 DTEND;TZID=Europe/Berlin:20131012T153000 SUMMARY:Workshop 8 - Somatic aberrations, epigenetic mechanisms and deregulated gene expression LOCATION:Severin (Dorint Hotel) DESCRIPTION:Talks: Novel and recurrent coding sequence mutations in microdissected Hodgkin-/ Reed- Sternberg cells, No chance for a comeback? The multiple ways to block the B-cell phenotype in Hodgkin Lymphoma, New insights into the transcription factor network of Hodgkin-/ Reed-Sternberg cells, Transcriptome analysis of Hodgkin and Reed-Sternberg cells enriched from Hodgkin Lymphoma biopsies: an approach to virus discovery, Downregulation of FOXO1 prevents induction of the tumor suppressor PRDM1 in cHL X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Workshop 8 - Somatic aberrations, epigenetic mechanisms and deregulated gene expression ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260414T234200 UID:session-51@app.ishl.eu/2013 DTSTART;TZID=Europe/Berlin:20131012T160000 DTEND;TZID=Europe/Berlin:20131012T173000 SUMMARY:Workshop 9 - Integrating PET into the management of early stage HL LOCATION:Pipin I (Dorint Hotel) DESCRIPTION:Talks: Introduction, RAPID trial: Update and lessons in standardized interpretation of PET, BCCA experience: Population-based PET guided treatment, Challenges applying PET for early stage disease, What did EORTC H10 teach us?, Formulation of conclusions and identi cation of important outstanding questions X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Workshop 9 - Integrating PET into the management of early stage HL ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260414T234200 UID:session-56@app.ishl.eu/2013 DTSTART;TZID=Europe/Berlin:20131012T160000 DTEND;TZID=Europe/Berlin:20131012T173000 SUMMARY:Workshop 10 - International Guidelines on Follow-up and Survivorship LOCATION:Martin & Augustin (Dorint Hotel) DESCRIPTION:Talks: Some “philosophical” introductoryremarkson the need and pitfalls of long-term follow-up, The ASCO and the Dutch guidelines, Minimizing treatment and its consequences for long term toxicity and follow-up, Reducing RT to involved node principle and its consequences for long-term toxicity and follow-up, General discussion X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Workshop 10 - International Guidelines on Follow-up and Survivorship ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260414T234200 UID:session-57@app.ishl.eu/2013 DTSTART;TZID=Europe/Berlin:20131012T160000 DTEND;TZID=Europe/Berlin:20131012T173000 SUMMARY:Workshop 11 - Genetic predisposition – HLA, GWAS, secondary malignancies, prognostic LOCATION:Severin (Dorint Hotel) DESCRIPTION:Talks: Familial risks and germline genetics of Hodgkin Lymphoma, HLA locus and risk of Hodgkin Lymphoma, Multiple neoplasias a er Hodgkin Lymphoma; incidence and risk factors, Genetic defects of T-cell function predisposing for EBV-associated lymphoproliferation and Hodgkin Lymphoma, General discussion X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Workshop 11 - Genetic predisposition – HLA, GWAS, secondary malignancies, prognostic ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260414T234200 UID:session-58@app.ishl.eu/2013 DTSTART;TZID=Europe/Berlin:20131012T180000 DTEND;TZID=Europe/Berlin:20131012T190000 SUMMARY:Workshop 12 - Targeted Therapy: The Future in the Treatment of Malignant Lymphoma LOCATION:Pipin I (Dorint Hotel) DESCRIPTION:Talks: New approaches in the treatment of mantle cell and other Non Hodgkin Lymphoma, New horizons in the treatment o CLL X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Workshop 12 - Targeted Therapy: The Future in the Treatment of Malignant Lymphoma ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260414T234200 UID:session-59@app.ishl.eu/2013 DTSTART;TZID=Europe/Berlin:20131013T073000 DTEND;TZID=Europe/Berlin:20131013T083000 SUMMARY:Satellite Symposium - Novel Methodology to aid in the Diagnosis of Difficult Hodgkin Lymphoma Cases LOCATION:Großer Saal DESCRIPTION:Talks: Introduction and Perspective, Novel methodology to aid in the diagnosis of di cult lymphoma cases, Case Series Presentation using MultiOmyx Methodology, Questions & Answers X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Satellite Symposium - Novel Methodology to aid in the Diagnosis of Difficult Hodgkin Lymphoma Cases ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260414T234200 UID:session-60@app.ishl.eu/2013 DTSTART;TZID=Europe/Berlin:20131013T083000 DTEND;TZID=Europe/Berlin:20131013T100000 SUMMARY:Scientific Session 1 - Interactive Case Discussions LOCATION:Großer Saal DESCRIPTION: X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 1 - Interactive Case Discussions ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260414T234200 UID:session-61@app.ishl.eu/2013 DTSTART;TZID=Europe/Berlin:20131013T103000 DTEND;TZID=Europe/Berlin:20131013T120000 SUMMARY:Scientific Session 2 - Pathways LOCATION:Großer Saal DESCRIPTION:Talks: JAK / STAT, Non-coding RNA and tumor cell survival, CSF1 and CSF1R, Integrated genomic analysis of ow sorted Hodgkin and Reed-Sternberg cell in primary classical Hodgkin Lymphoma, TCF3 / E2A (19p13.3) is a novel Hodgkin Lymphoma susceptibility locus; a meta-GWAS study from the InterLymph Hodgkin Lymphoma consortium, Hodgkin-Reed-Sternberg cells in classical Hodgkin Lymphoma show alterations of genes encoding the NADPH oxidase complex and impaired reactive oxygen species synthesis capacity X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 2 - Pathways ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260414T234200 UID:session-62@app.ishl.eu/2013 DTSTART;TZID=Europe/Berlin:20131013T121500 DTEND;TZID=Europe/Berlin:20131013T134500 SUMMARY:Satellite Symposium - Lenalidomide in Lymphoma – Latest Update on Clinical Data LOCATION:Großer Saal DESCRIPTION:Talks: Rationale and Clinical Experience with Lenalidomide in Hodgkin Lymphoma, Progress in the treatment of Aggressive B-Cell Lymphomas, Emerging treatment options for mantle cell lymphoma X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Satellite Symposium - Lenalidomide in Lymphoma – Latest Update on Clinical Data ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260414T234200 UID:session-64@app.ishl.eu/2013 DTSTART;TZID=Europe/Berlin:20131013T140000 DTEND;TZID=Europe/Berlin:20131013T151500 SUMMARY:Satellite Symposium - New Insights in the Treatment and Management of Lymphoid Malignancies LOCATION:Großer Saal DESCRIPTION:Talks: New Aspects on Dose Density in Malignant Lymphoma, The impact of hematological toxicity in Hodgkin Lymphoma, Bispeci c CD19 antibodies – a new treatment principle for management of relapsed / refractory ALL and NHL X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Satellite Symposium - New Insights in the Treatment and Management of Lymphoid Malignancies ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260414T234200 UID:session-65@app.ishl.eu/2013 DTSTART;TZID=Europe/Berlin:20131013T160000 DTEND;TZID=Europe/Berlin:20131013T173000 SUMMARY:Satellite Symposium - Relapsed/Refractory Hodgkin Lymphoma: Exploring Targeted Therapeutic Options LOCATION:Großer Saal DESCRIPTION:Talks: Welcome and Introduction, The challenge of relapsed Hodgkin Lymphoma in the era of contemporary therapy, Q&A, Defining the ideal target in Hodgkin Lymphoma, Q&A, Targeting CD30 with monoclonal antibody- based constructs, Q&A, Current success and future opportunities with targeted therapy in Hodgkin Lymphoma, Q&A, Closing comments X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Satellite Symposium - Relapsed/Refractory Hodgkin Lymphoma: Exploring Targeted Therapeutic Options ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260414T234200 UID:session-66@app.ishl.eu/2013 DTSTART;TZID=Europe/Berlin:20131013T180000 DTEND;TZID=Europe/Berlin:20131013T200000 SUMMARY:Main Program - Opening Ceremony LOCATION:Großer Saal DESCRIPTION:Talks: Bonadonna Lecture: The Hodgkin puzzle: Are we getting close?, Awards Ceremony X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Main Program - Opening Ceremony ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260414T234200 UID:session-67@app.ishl.eu/2013 DTSTART;TZID=Europe/Berlin:20131013T200000 SUMMARY:Main Program - Get Together LOCATION:Weinkeller DESCRIPTION: X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Main Program - Get Together ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260414T234200 UID:session-68@app.ishl.eu/2013 DTSTART;TZID=Europe/Berlin:20131014T073000 DTEND;TZID=Europe/Berlin:20131014T083000 SUMMARY:Satellite Symposium - Beyond the revolution of MabThera LOCATION:Großer Saal DESCRIPTION:Talks: Do we have a new backbone in CLL?, Can we make MabThera better? X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Satellite Symposium - Beyond the revolution of MabThera ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260414T234200 UID:session-69@app.ishl.eu/2013 DTSTART;TZID=Europe/Berlin:20131014T083000 DTEND;TZID=Europe/Berlin:20131014T100000 SUMMARY:Scientific Session 3 - Biology and Microenvironment LOCATION:Großer Saal DESCRIPTION:Talks: Microenvironment in Hodgkin Lymphoma, Molecular pathogenesis of Hodgkin Lymphoma, Deregulation of di erentiation in pathogenesis of cHL, Plasma microRNA are disease response biomarkers in classical Hodgkin Lymphoma, CD57+ T cells in nodular lymphocyte predominant Hodgkin Lymphoma are T-follicular helper cells, Analysis of myeloid suppressor marker Arginase identi es CD68+ / Arginase+ myeloid / monocytic subsets and exerts stronger prognostic in uence than macrophage quanti cation in Classical Hodgkin Lymphoma X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 3 - Biology and Microenvironment ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260414T234200 UID:session-70@app.ishl.eu/2013 DTSTART;TZID=Europe/Berlin:20131014T103000 DTEND;TZID=Europe/Berlin:20131014T120000 SUMMARY:Scientific Session 4 - Early Stages LOCATION:Großer Saal DESCRIPTION:Talks: Update on the NCRI RAPID trial, An update on the EORTC / LYSA / FIL H10 trial, WS report and further optimization in early stage Hodgkin Lymphoma, Impact of bleomycin and dacarbazine within the ABVD regimen in the treatment of early-stage favorable Hodgkin Lymphoma: Final results of the GHSG HD13 trial, De nition of bulky disease in early stage Hodgkin Lymphoma in computed tomography era: Prognostic signi cance of measurements in the coronal and transverse planes, Brentuximab vedotin plus AVD as initial therapy of non-bulky limited stage classical Hodgkin Lymphoma: Interim analysis of an ongoing phase II trial X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 4 - Early Stages ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260414T234200 UID:session-71@app.ishl.eu/2013 DTSTART;TZID=Europe/Berlin:20131014T121500 DTEND;TZID=Europe/Berlin:20131014T134500 SUMMARY:Satellite Symposium - NHL and G-CSF – Focus on optimising the results LOCATION:Großer Saal DESCRIPTION:Talks: Introduction “Let’s get interactive”, Do we need G-CSF in Lymphoma Therapy?, How much G-CSF is necessary in Lymphoma Therapy?, Current clinical Lymphoma trials based on G-CSF, Innovation and Best Practice – how to bene t X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Satellite Symposium - NHL and G-CSF – Focus on optimising the results ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260414T234200 UID:session-72@app.ishl.eu/2013 DTSTART;TZID=Europe/Berlin:20131014T140000 DTEND;TZID=Europe/Berlin:20131014T153000 SUMMARY:Scientific Session 5 - Hodgkin lymphoma in older patients LOCATION:Großer Saal DESCRIPTION:Talks: Epidemiology and biology, First line treatment, Relapsed / refractory Hodgkin Lymphoma in older patients, GHSH phase I / II trial of AVD-Rev (adriamycin, vinblastin, dacarbacine and lenalidomide) for older Hodgkin Lymphoma patients, Sequential brentuximab vedotin (BV) and adriamycin, vinblastine, and dacarbazine (AVD) for older patients with untreated Hodgkin Lymphoma (HL): Preliminary toxicity ndings from a phase II window study, Treatment outcome in 111 elderly patients with Hodgkin Lymphoma: a retrospective analysis X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 5 - Hodgkin lymphoma in older patients ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260414T234200 UID:session-73@app.ishl.eu/2013 DTSTART;TZID=Europe/Berlin:20131014T154500 DTEND;TZID=Europe/Berlin:20131014T173000 SUMMARY:Scientific Session 6 - PET and prediction LOCATION:Großer Saal DESCRIPTION:Talks: PET for early response prediction, PET review in GHSG trials, PETinrelapsedorrefractoryHodgkinLymphoma, Response-adapted therapy of stage III-IV Hodgkin lymphoma based on interim FDG-PET imaging: early results of US intergroup S0816, Very early response as measured by (18F)- uorodeoxyglucose-positron emission tomography (FDG-PET) a er one cycle of chemotherapy in newly diagnosed pediatric / adolescent low risk Hodgkin Lymphoma (HL), Tailored therapy in Hodgkin Lymphoma, based on prede ned risk factors and early interim PET / CT, Israeli H2 protocol: Preliminary report on 317 patients X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 6 - PET and prediction ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260414T234200 UID:session-74@app.ishl.eu/2013 DTSTART;TZID=Europe/Berlin:20131014T174500 DTEND;TZID=Europe/Berlin:20131014T191500 SUMMARY:Satellite Symposium - Defining Therapeutic Targets in T-Cell Lymphoma LOCATION:Großer Saal DESCRIPTION:Talks: Welcome and Introduction, Traditional Approaches to T-cell Lymphoma, Q&A, Transition with targeted agents in T-cell Lymphoma, Q&A, Targeting CD30 in T-cell Lymphoma, Q&A, Challenging the experts: An interactive panel discussion, Adjourn X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Satellite Symposium - Defining Therapeutic Targets in T-Cell Lymphoma ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260414T234200 UID:session-75@app.ishl.eu/2013 DTSTART;TZID=Europe/Berlin:20131015T073000 DTEND;TZID=Europe/Berlin:20131015T090000 SUMMARY:Workshop 13 - Beyond the International Harmonization Criteria – New challenges in the application of imaging techniques for staging and response LOCATION:Großer Saal DESCRIPTION:Talks: Practical experience in the application of the International Harmonization Criteria – as viewed by a medical oncologist, Anatomic imaging challenges of the International Harmonization Criteria, Nuclear medicine aspects of the International Harmonization Criteria, as they apply to pediatrics, Overview of the challenges encountered by the Pediatric International Harmonization Criteria Workshop, Discussion X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Workshop 13 - Beyond the International Harmonization Criteria – New challenges in the application of imaging techniques for staging and response ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260414T234200 UID:session-76@app.ishl.eu/2013 DTSTART;TZID=Europe/Berlin:20131015T090000 DTEND;TZID=Europe/Berlin:20131015T103000 SUMMARY:Scientific Session 7 - Survivorship LOCATION:Großer Saal DESCRIPTION:Talks: Cardiac toxicity, Breast Cancer and other Neoplasms, Fertility, Changes in breast cancer risk as long-term Hodgkin Lymphoma survivors reach menopausal age, Second cancer risk forty years a er cure for Hodgkin Lymphoma, A Dutch nationwide survivorship care programme for Hodgkin Lymphoma survivors X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 7 - Survivorship ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260414T234200 UID:session-77@app.ishl.eu/2013 DTSTART;TZID=Europe/Berlin:20131015T110000 DTEND;TZID=Europe/Berlin:20131015T123000 SUMMARY:Scientific Session 8 - Advanced Stages LOCATION:Großer Saal DESCRIPTION:Talks: Risk-adapted therapy in advanced stage Hodgkin Lymphoma: An Update, Can we improve ABVD?, Can we improve BEACOPP?, Impact of dose reductions of bleomycin and vincristine in patients with advanced Hodgkin Lymphoma treated with BEACOPP polychemotherapy: A comprehensive analysis of the German Hodgkin Study Group (GHSG) HD12 and HD15 trials, Standard ABVD vs. escalated BEACOPP in stage III – IV low risk Hodgkin Lymphoma (IPS 0-2): the Lymphoma Study Association (LYSA) H34 trial, Response rates and toxicity of response-adapted therapy in advanced Hodgkin Lymphoma: initial results from the international RATHL study X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 8 - Advanced Stages ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260414T234200 UID:session-78@app.ishl.eu/2013 DTSTART;TZID=Europe/Berlin:20131015T124500 DTEND;TZID=Europe/Berlin:20131015T141500 SUMMARY:Satellite Symposium - Update on Infectious Diseases in Hematology Patients LOCATION:Großer Saal DESCRIPTION:Talks: Introduction, Clinical infectious challenges in patients with Hodgkin Lymphoma, Present and upcoming vaccines for the immunocomprised host, Focussing on unmet medical needs in abdominal infections, Discussion and Summary X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Satellite Symposium - Update on Infectious Diseases in Hematology Patients ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260414T234200 UID:session-79@app.ishl.eu/2013 DTSTART;TZID=Europe/Berlin:20131015T134500 DTEND;TZID=Europe/Berlin:20131015T141500 SUMMARY:Main Program - Poster Walk LOCATION:Kleiner Saal DESCRIPTION: X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Main Program - Poster Walk ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260414T234200 UID:session-80@app.ishl.eu/2013 DTSTART;TZID=Europe/Berlin:20131015T143000 DTEND;TZID=Europe/Berlin:20131015T160000 SUMMARY:Scientific Session 9 - Relapsed LOCATION:Großer Saal DESCRIPTION:Talks: What’s new in relapsed Hodgkin Lymphoma?, Debate: Is there still a role for allogeneic TX in Hodgkin Lymphoma?, Phase 2 study everolimus for relapsed / refractory classical Hodgkin Lymphoma (cHL), Outcome of patients treated with autologous stem-cell transplantation for rst relapsed or refractory Hodgkin Lymphoma: A long-term analysis of the prospective LYSA / SFGM-TC H96 trial, PET adapted sequential salvage therapy with brentuximab vedotin and augmented ICE for transplant eligible patients with relapsed and refractory Hodgkin Lymphoma X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 9 - Relapsed ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260414T234200 UID:session-83@app.ishl.eu/2013 DTSTART;TZID=Europe/Berlin:20131015T161500 DTEND;TZID=Europe/Berlin:20131015T180000 SUMMARY:Scientific Session 10 - Milestones in Hodgkin Lymphoma LOCATION:Großer Saal DESCRIPTION:Talks: Pathology, Basic research, Prognostic indices and PET, Radiotherapy, Clinical trials, New drugs X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 10 - Milestones in Hodgkin Lymphoma ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260414T234200 UID:session-84@app.ishl.eu/2013 DTSTART;TZID=Europe/Berlin:20131015T180000 DTEND;TZID=Europe/Berlin:20131015T183000 SUMMARY:Main Program - Closing Remakrs LOCATION:Großer Saal DESCRIPTION: X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Main Program - Closing Remakrs ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT END:VCALENDAR